Schrödinger have developed a unique platform that integrates predictive physics-based methods with machine learning techniques to accelerate the process of drug discovery. This platform is designed to evaluate and optimize chemical matter in silico ahead of synthesis and assay, which allows for the rapid identification of potent molecules suitable to initiate hit-to-lead and lead optimization efforts.

In the realm of drug discovery, Schrödinger’s platform has proven to be a game-changer. It enables the discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost compared to traditional methods. The most promising compounds emerging from each round of experimental project chemistry are then further optimized through additional cycles of computation analysis.